Last reviewed · How we verify

NCT07406022: OpticSkin

Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis.

Not yet recruiting Last updated 12 February 2026
What this trial tests

trial in Skin Cancer in 140 participants. Not yet recruiting.

Timeline
1 February 2026
Primary endpoint
31 December 2029
31 December 2029

Quick facts

Lead sponsorCentre Hospitalier Régional Metz-Thionville
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment140
Start date1 February 2026
Primary completion31 December 2029
Estimated completion31 December 2029
Sites1 location across France

Conditions studied

Sponsor

Centre Hospitalier Régional Metz-Thionville

Who can join

18 and older, any sex, with Skin Cancer or Diagnostic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Skin carcinomas are the most commonly diagnosed cancers in fair-skinned populations, for example in France, Western Europe, and North America in particular. The OpticSkin project will build and make available to the general public and the scientific and medical community a histological and optical spectroscopic database of healthy, precancerous, and cancerous human skin in terms of absorption, elastic and inelastic scattering (Raman), steady-state and time-resolved autofluorescence, and polarization. The aim is to identify spectroscopic signatures that will be useful for diagnosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Skin Cancer

Currently open trials in the same condition.

Other Centre Hospitalier Régional Metz-Thionville trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07406022.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing